Cargando…

Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies

BACKGROUND: Glutathione S-transferase P1 (GSTP1) has been reported to function as a tumor suppressor gene in various types of human cancers. Aberrant methylation of tumor-related genes at the promoter regions can inactivate genes, which is important in the carcinogenesis of breast cancer. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Cheng, Wei, Xue-Mei, Zeng, Xian-Tao, Wang, Fu-Bing, Weng, Hong, Long, Xinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653831/
https://www.ncbi.nlm.nih.gov/pubmed/26585467
http://dx.doi.org/10.1186/s12885-015-1926-1
_version_ 1782401981333110784
author Fang, Cheng
Wei, Xue-Mei
Zeng, Xian-Tao
Wang, Fu-Bing
Weng, Hong
Long, Xinghua
author_facet Fang, Cheng
Wei, Xue-Mei
Zeng, Xian-Tao
Wang, Fu-Bing
Weng, Hong
Long, Xinghua
author_sort Fang, Cheng
collection PubMed
description BACKGROUND: Glutathione S-transferase P1 (GSTP1) has been reported to function as a tumor suppressor gene in various types of human cancers. Aberrant methylation of tumor-related genes at the promoter regions can inactivate genes, which is important in the carcinogenesis of breast cancer. However, the role of GSTP1 promoter methylation in the occurrence of breast cancer and its relationship with tumor stage and histological grade has not been fully elucidated. Thus, we carried out a meta-analysis to yield a more accurate association. METHODS: A systematically literature search was made on PubMed, EMBASE and Web of Science databases for eligible studies. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated by RevMan 5.2 software. Subgroup and sensitivity analyses were conducted to explore the source of heterogeneity. RESULTS: Eventually, 17 articles involving 19 case–control studies were included in the present meta-analysis. Overall, the pooled results indicated that aberrant GSTP1 promoter methylation was significantly associated with the risk of breast cancer (OR = 7.85, 95 % CI = 5.12–12.01; Caucasians OR = 7.23, 95 % CI = 3.76–13.90 and Asians OR = 11.71, 95 % CI = 5.69–24.07). Furthermore, our results revealed that GSTP1 promoter methylation was more often observed in late-stage breast cancer patients compared with early-stage ones (OR = 1.84, 95 % CI = 1.32–2.58). However, no significant association was identified between GSTP1 promoter methylation and histological grade (OR = 0.74, 95 % CI = 0.43–1.26). CONCLUSIONS: The results indicated that GSTP1 promoter methylation probably plays an important role in breast carcinogenesis, which could serve as an effective biomarker for the diagnosis and monitor of breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1926-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4653831
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46538312015-11-21 Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies Fang, Cheng Wei, Xue-Mei Zeng, Xian-Tao Wang, Fu-Bing Weng, Hong Long, Xinghua BMC Cancer Research Article BACKGROUND: Glutathione S-transferase P1 (GSTP1) has been reported to function as a tumor suppressor gene in various types of human cancers. Aberrant methylation of tumor-related genes at the promoter regions can inactivate genes, which is important in the carcinogenesis of breast cancer. However, the role of GSTP1 promoter methylation in the occurrence of breast cancer and its relationship with tumor stage and histological grade has not been fully elucidated. Thus, we carried out a meta-analysis to yield a more accurate association. METHODS: A systematically literature search was made on PubMed, EMBASE and Web of Science databases for eligible studies. The odds ratio (OR) and 95 % confidence interval (95 % CI) were calculated by RevMan 5.2 software. Subgroup and sensitivity analyses were conducted to explore the source of heterogeneity. RESULTS: Eventually, 17 articles involving 19 case–control studies were included in the present meta-analysis. Overall, the pooled results indicated that aberrant GSTP1 promoter methylation was significantly associated with the risk of breast cancer (OR = 7.85, 95 % CI = 5.12–12.01; Caucasians OR = 7.23, 95 % CI = 3.76–13.90 and Asians OR = 11.71, 95 % CI = 5.69–24.07). Furthermore, our results revealed that GSTP1 promoter methylation was more often observed in late-stage breast cancer patients compared with early-stage ones (OR = 1.84, 95 % CI = 1.32–2.58). However, no significant association was identified between GSTP1 promoter methylation and histological grade (OR = 0.74, 95 % CI = 0.43–1.26). CONCLUSIONS: The results indicated that GSTP1 promoter methylation probably plays an important role in breast carcinogenesis, which could serve as an effective biomarker for the diagnosis and monitor of breast cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1926-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-19 /pmc/articles/PMC4653831/ /pubmed/26585467 http://dx.doi.org/10.1186/s12885-015-1926-1 Text en © Fang et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fang, Cheng
Wei, Xue-Mei
Zeng, Xian-Tao
Wang, Fu-Bing
Weng, Hong
Long, Xinghua
Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
title Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
title_full Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
title_fullStr Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
title_full_unstemmed Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
title_short Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
title_sort aberrant gstp1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653831/
https://www.ncbi.nlm.nih.gov/pubmed/26585467
http://dx.doi.org/10.1186/s12885-015-1926-1
work_keys_str_mv AT fangcheng aberrantgstp1promotermethylationisassociatedwithincreasedriskandadvancedstageofbreastcancerametaanalysisof19casecontrolstudies
AT weixuemei aberrantgstp1promotermethylationisassociatedwithincreasedriskandadvancedstageofbreastcancerametaanalysisof19casecontrolstudies
AT zengxiantao aberrantgstp1promotermethylationisassociatedwithincreasedriskandadvancedstageofbreastcancerametaanalysisof19casecontrolstudies
AT wangfubing aberrantgstp1promotermethylationisassociatedwithincreasedriskandadvancedstageofbreastcancerametaanalysisof19casecontrolstudies
AT wenghong aberrantgstp1promotermethylationisassociatedwithincreasedriskandadvancedstageofbreastcancerametaanalysisof19casecontrolstudies
AT longxinghua aberrantgstp1promotermethylationisassociatedwithincreasedriskandadvancedstageofbreastcancerametaanalysisof19casecontrolstudies